Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cumberland Pharmaceuticals (CPIX) Tops Q4 EPS and Revenue
February 26, 2019 4:35 PM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of $0.10, $0.26 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $10.98 million.
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
... More